Desferrioxamine, an iron chelator, enhances HIF-1α accumulation via cyclooxygenase-2 signaling pathway

Biochemical and Biophysical Research Communications

Volumn 343, Issue 1, 2006, Pages 8-14

  Woo, Kyung Jin ^a   Lee, Tae Jin ^a   Park, Jong Wook ^a   Kwon, Taeg Kyu ^a  

^a Keimyung University   (South Korea)

Author keywords

Colon cancer; COX 2; Desferrioxamine; ERK; HIF 1

Indexed keywords

COBALT CHLORIDE; CYCLOOXYGENASE 2; DEFEROXAMINE; FERRIC CITRATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON CHELATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UPREGULATION;

ANOXIA; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DEFEROXAMINE; FERRIC COMPOUNDS; FLAVONOIDS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON CHELATING AGENTS; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 33645105323     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.02.116     Document Type: Article

References (42)

1. R.N. Dubois, S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, L.B. Van De Putte, and P.E. Lipsky Cyclooxygenase in biology and disease FASEB J. 12 1998 1063 1073
2. W.L. Smith, and R. Langenbach Why there are two cyclooxygenase isozymes J. Clin. Invest. 107 2001 1491 1495
3. C.S. Williams, M. Mann, and R.N. DuBois The role of cyclooxygenases in inflammation, cancer, and development Oncogene 18 1999 7908 7916
4. H.S. Kim, H.R. Youm, J.S. Lee, K.W. Min, J.H. Chung, and C.S. Park Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer Lung Cancer 42 2003 163 170
5. C. Denkert, K.J. Winzer, B.M. Muller, W. Weichert, S. Pest, M. Kobel, G. Kristiansen, A. Reles, A. Siegert, H. Guski, and S. Hauptmann Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma Cancer 97 2003 2978 2987
6. A. Ristimaki, K. Narko, and T. Hla Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation Biochem. J. 318 1996 325 331
7. S.A. Weitzman, and L.I. Gordon Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis Blood 76 1990 655 663
8. G.U. Dachs, and D.J. Chaplin Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis Semin. Radiat. Oncol. 8 1998 208 216
9. M. Gassmann, J. Fandrey, S. Bichet, M. Wartenberg, H.H. Marti, C. Bauer, R.H. Wenger, and H. Acker Oxygen supply and oxygen-dependent gene expression in differentiating embryonic stem cells Proc. Natl. Acad. Sci. USA 93 1996 2867 2872
10. N.M. Hasan, G.E. Adams, M.C. Joiner, J.F. Marshall, and I.R. Hart Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability Br. J. Cancer 77 1998 1799 1805
11. J. Yuan, and P.M. Glazer Mutagenesis induced by the tumor microenvironment Mutat. Res. 400 1998 439 446
12. R.H. Wenger Mammalian oxygen sensing, signalling, and gene regulation J. Exp. Biol. 203 2000 1253 1263
13. C. Lewis, and C. Murdoch Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies Am. J. Pathol. 167 2005 627 635
14. G.L. Semenza HIF-1 and tumor progression: pathophysiology and therapeutics Trends Mol. Med. 8 Suppl. 4 2002 S62 S67
15. S.P. Huang, M.S. Wu, C.T. Shun, H.P. Wang, C.Y. Hsieh, M.L. Kuo, and J.T. Lin Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma J. Biomed. Sci. 12 2005 229 241
16. M. Dlaska, and G. Weiss Central role of transcription factor NF-IL6 for cytokine and iron-mediated regulation of murine inducible nitric oxide synthase expression J. Immunol. 162 1999 6171 6177
17. A.R. O'Brien-Ladner, B.M. Blumer, and L.J. Wesselius Differential regulation of human alveolar macrophage-derived interleukin-1β and tumor necrosis factor-α by iron J. Lab. Clin. Med. 132 1998 497 506
18. X.H. Liu, A. Kirschenbaum, K. Yu, S. Yao, and A.C. Levine Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line J. Biol. Chem. 280 2005 3817 3823
19. K. Tanji, T. Imaizumi, T. Matsumiya, H. Itaya, K. Fujimoto, X. Cui, T. Toki, E. Ito, H. Yoshida, K. Wakabayashi, and K. Satoh Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line Biochim. Biophys. Acta 1530 2001 227 235
20. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 3 2003 721 732
21. L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids Anal. Biochem. 126 1982 131 138
22. P. Chomczynski, and N. Sacchi Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal. Biochem. 162 1987 156 159
23. Y. Yuan, G. Hilliard, T. Ferguson, and D.E. Millhorn Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha J. Biol. Chem. 278 2003 15911 15916
24. K. Subbaramaiah, N. Altorki, W.J. Chung, J.R. Mestre, A. Sampat, and A.J. Dannenberg Inhibition of cyclooxygenase-2 gene expression by p53 J. Biol. Chem. 274 1999 10911 10915
25. M.V. Blagosklonny, W.G. An, L.Y. Romanova, J. Trepe, T. Fojo, and L. Neckers Links p53 inhibits hypoxia-inducible factor-stimulated transcription J. Biol. Chem. 273 1998 11995 11998
26. L.A. Jimenez, J. Thompson, D.A. Brown, I. Rahman, F. Antonicelli, R. Duffin, E.M. Drost, R.T. Hay, K. Donaldson, and W. MacNee Activation of NF-κB by PM(10) occurs via an iron-mediated mechanism in the absence of IκB degradation Toxicol. Appl. Pharmacol. 166 2000 101 110
27. K. Yamashita, D.J. Discher, J. Hu, N.H. Bishopric, and K.A. Webster Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP J. Biol. Chem. 276 2001 12645 12653
28. K.B. Sandau, J. Fandrey, and B. Brune Accumulation of HIF-1α under the influence of nitric oxide Blood 97 2001 1009 1015
29. D.P. Stiehl, W. Jelkmann, R.H. Wenger, and T. Hellwig-Burgel Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway FEBS Lett. 512 2002 157 162
30. K.B. Sandau, J. Zhou, T. Kietzmann, and B. Brune Regulation of the hypoxia-inducible factor 1α by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferrioxamine and phenylarsine oxide J. Biol. Chem. 276 2001 39805 39811
31. N.J. Mabjeesh, M.T. Willard, W.B. Harris, H.Y. Sun, R. Wang, H. Zhong, J.N. Umbreit, and J.W. Simons Dibenzoylmethane, a natural dietary compound, induces HIF-1α and increases expression of VEGF Biochem. Biophys. Res. Commun. 303 2003 279 286
32. P.J. Kallio, W.J. Wilson, S. O'Brien, Y. Makino, and L. Poellinger Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway J. Biol. Chem. 274 1999 6519 6525
33. L.E. Huang, J. Gu, M. Schau, and H.F. Bunn Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway Proc. Natl. Acad. Sci. USA 95 1998 7987 7992
34. S. Salceda, and J. Caro Hypoxia-inducible factor 1α (HIF-α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes J. Biol. Chem. 272 1997 22642 22647
35. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 New Engl. J. Med. 345 2001 433 442
36. A.J. Dannenberg, N.K. Altorki, J.O. Boyle, C. Dang, L.R. Howe, B.B. Weksler, and K. Subbaramaiah Cyclooxygenase 2: a pharmacological target for the prevention of cancer Lancet Oncol. 2 2001 544 551
37. M.A Iniguez, A. Rodriguez, O.V. Volpert, M. Fresno, and J.M. Redondo Cyclooxygenase-2: a therapeutic target in angiogenesis Trends Mol. Med. 9 2003 73 78
38. H. Keberle The biochemistry of desferrioxamine and its relation to iron metabolism Ann. N Y Acad. Sci. 119 1964 758 768
39. P. Pichiule, J.C. Chavez, and J.C. LaManna Hypoxic regulation of angiopoietin-2 expression in endothelial cells J. Biol. Chem. 279 2004 12171 12180
40. H. Zhong, M. Willard, and J. Simons NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms Int. J. Cancer 112 2004 585 595
41. P.A. Scherle, E.A. Jones, M.F. Favata, A.J. Daulerio, M.B. Covington, S.A. Nurnberg, R.L. Magolda, and J.M. Trzaskos Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide- stimulated monocytes J. Immunol. 161 1998 5681 5686
42. S.R. Bartlett, R. Sawdy, and G.E. Mann Induction of cyclooxygenase-2 expression in human myometrial smooth muscle cells by interleukin-1β: involvement of p38 mitogen-activated protein kinase J. Physiol. 520 Pt. 2 1999 399 406